Compare Medtronic PLC (MDT) vs Microsoft (MSFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Microsoft — how do they compare? Medtronic PLC trades at $88.22 (market cap $112.24B), while Microsoft trades at $533.96 (market cap $3.88T). The key difference: Microsoft is far larger — about 34.6× Medtronic PLC's market cap, and Medtronic PLC pays the higher dividend (3.28%). Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and Microsoft for 142 Days on average.
| MDT | MSFT | |
|---|---|---|
Market Cap | $112.24B | $3.88T |
Volume | 105,663,236 | 19,593,392 |
Sector | Health | Technology |
52-Week High | $105.35 | $542.07 |
52-Week Low | $73.75 | $352.83 |
Typical Hold Time | 63 Days | 142 Days |
Enterprise Value | $131.58B | $3.86T |
Dividend Yield | 3.28% | 0.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $87.80, up 2.68% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a 13.93% net income margin and consistent dividend growth over 49 years. Revenue growth accelerated to $33.54B in 2025, and analyst consensus targets $97.80, implying 11% upside. Recent news highlights regulatory approvals for medical devices and a $4B MiniMed exchange offer.
MDT offers value with a 3.2% dividend yield and reasonable valuation (P/E 21.6), but faces headwinds from technical bearishness and rising debt. The stock's appeal hinges on execution of growth initiatives in cardiovascular and neuroscience segments, though competitive and macroeconomic risks persist.
Microsoft (MSFT) trades at $534.75, up 0.94% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $4.74 surpassing the $4.24 expectation. Revenue grew to $281.72 billion in 2025, and net income reached $101.83 billion, reflecting a robust 40.31% net margin. Analysts maintain a strong buy consensus with an average price target of $571.76, indicating potential upside from current levels.
The outlook for Microsoft remains positive, driven by AI leadership, Azure cloud growth, and solid cash flow generation. Key opportunities include expanding AI services and cloud market share, while risks involve high capital expenditures, competitive pressures, and macroeconomic volatility. The stock's valuation multiples, such as a P/E of 29.11, are elevated but supported by earnings growth and market position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →
